Glucagon-Like Peptide-1 Agonist Risks and Complications in Critically Ill and Perioperative Patients

The off-label use of glucagon-like peptide 1 (GLP-1) agonists has dramatically increased due to its weight loss properties. The use has also significantly increased in patients with diabetes due to a reduced risk for cardiovascular events. GLP-1 agonists cause a significant decrease in gastric emptying rate, which can increase the risk of aspiration during intubation, general anesthesia, and deep sedation. Other serious and rare side effects such as gallbladder and biliary tract diseases and acute pancreatitis may also occur. This session will provide an overview on pharmacology, indications, and management strategies of possible complications of GLP-1 agonists that may occur in critically ill and perioperative patients.